Introduction Zasocitinib, a next-generation oral TYK2 inhibitor, is setting a new benchmark in the treatment of moderate-to-severe psoriasis. In a recent comparative analysis, Zasocitinib demonstrated greater potency, superior selectivity, and prolonged TYK2 inhibition compared to other approved TYK2/JAK inhibitors, including deucravacitinib, baric
65 Reached4 Comments
Woman presented with Fever of Unknown Origin
7717 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Rubella Syndrome in Neonate
1396 Reached12 Comments9 Likes
Black Lesion in Old Female
1970 Reached5 Comments11 Likes
Chronic Hyperplastic Candidiasis Of The Oral Mucosa
857 Reached9 Comments11 Likes